15 completed, 3 active not recruiting, 1 unknown, 1 withdrawn. 20 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 15, Active not recruiting 3, Unknown 1, Withdrawn 1 |
| Phase 3 | 3 | Active not recruiting 2, Completed 1 |
Follow Flutamide: new trials by email Literature Review of Flutamide trials Research Report on Flutamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis | Phase 2 / Phase 3 | Active not recruiting | VA Office of Research and Development | 378 | 2021-07-01 | 2026-10-19 |
| Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery Bicalutamide, Degarelix, Docetaxel - Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7 | Phase 2 / Phase 3 | Active not recruiting | NRG Oncology | 612 | 2017-04-05 | 2026-09-14 |
| Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) Bicalutamide, goserelin acetate, flutamide - Prostate Cancer | Phase 2 | Unknown | Fudan University | 200 | 2015-09-01 | 2020-07-07 |
| Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy. Enzalutamide, Flutamide - Castration-resistant Prostate Cancer | Phase 2 | Completed | Taro Iguchi, MD, PHD | 104 | 2014-12-01 | 2021-09-16 |
| Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Flutamide, Placebo - Polycystic Ovary Syndrome (PCOS) | Phase 2 | Completed | University of California, Los Angeles | 23 | 2013-04-01 | 2025-01-10 |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer Abiraterone Acetate, Bicalutamide, Degarelix - Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 310 | 2013-02-05 | 2026-08-11 |
| Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy bicalutamide, docetaxel, flutamide - Prostate Cancer | Phase 2 | Completed | Radiation Therapy Oncology Group | 80 | 2008-04-01 | 2019-04-24 |
| Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer Sargramostim (GM-CSF, Leukine), Flutamide (Eulexin), PROSTVAC-F/ TRICOM - Prostate Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 64 | 2007-02-23 | 2018-11-29 |
| Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer flutamide - Ovarian Cancer | Phase 2 | Completed | University of Arizona | 127 | 2005-01-01 | 2018-07-24 |
| Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Bicalutamide, Flutamide, Goserelin Acetate - Prostate Adenocarcinoma, Prostate Carcinoma | Phase 2 | Completed | Mayo Clinic | 112 | 2004-06-01 | 2017-05-15 |
| Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer. Flutamide, Finasteride, Placebo - Prostate Cancer, Prostatic Intraepithelial Neoplasia | Phase 2 / Phase 3 | Completed | Ente Ospedaliero Ospedali Galliera | 125 | 2004-01-01 | 2024-09-19 |
| Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen - Prostate Cancer | Phase 2 | Completed | University of Washington | 32 | 2002-03-12 | 2018-08-07 |
| S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer bicalutamide, estramustine, etoposide - Prostate Cancer | Phase 2 | Completed | SWOG Cancer Research Network | 41 | 2001-12-01 | 2013-07-16 |
| Flutamide In the Prevention of Prostate Cancer in Patients With Neoplasia of the Prostate flutamide, placebo - Prostate Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 63 | 2000-08-01 | 2016-07-13 |
| Hormone Therapy in Treating Patients With Prostate Cancer finasteride, flutamide, quality-of-life assessment - Prostate Cancer, Sexual Dysfunction and Infertility | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 101 | 1998-05-01 | 2016-07-04 |
| Hormone Therapy Plus Radiation Therapy in Treating Patients With Prostate Cancer flutamide, leuprolide acetate, radiation therapy - Prostate Cancer | Phase 2 | Completed | Herbert Irving Comprehensive Cancer Center | 105 | 1997-05-01 | 2014-01-06 |
| Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer flutamide, goserelin, leuprolide acetate - Prostate Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 180 | 1997-05-01 | 2023-08-18 |
| Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer Flutamide, Leuprolide Acetate - Prostate Cancer | Phase 2 | Completed | University of Washington | 102 | 1997-01-08 | 2018-08-07 |
| Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c Leuprorelin, Flutamide - Prostatic Neoplasms | Phase 2 | Completed | Takeda | 341 | 1996-12-01 | 2015-07-29 |
| Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer antineoplaston A10, antineoplaston AS2-1, bicalutamide - Adenocarcinoma of the Prostate, Stage III Prostate Cancer | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 |
Prostatic Neoplasms (16) · Amenorrhea (1) · Anovulation (1) · Carcinoma, Ovarian Epithelial (1) · Hirsutism (1) · Hyperandrogenism (1) · Infertility (1) · Neoplasm Metastasis (1) · Oligomenorrhea (1) · Ovarian Neoplasms (1) · Polycystic Ovary Syndrome (1) · Prostatic Intraepithelial Neoplasia (1) · Sexual Dysfunction, Physiological (1)
Alliance for Clinical Trials in Oncology (3) · University of Washington (2) · Burzynski Research Institute (1) · Ente Ospedaliero Ospedali Galliera (1) · Fudan University (1) · Herbert Irving Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · NRG Oncology (1) · National Cancer Institute (NCI) (1) · Radiation Therapy Oncology Group (1) · SWOG Cancer Research Network (1) · Takeda (1) · Taro Iguchi, MD, PHD (1) · University of Arizona (1)
United States (16) · Canada (3) · China (1) · Italy (1) · Japan (1) · Puerto Rico (1)
Celestia Higano, MD (2) · Abhishek Solanki, MD MS (1) · Andrea De Censi, MD (1) · Anthony V. D'Amico, MD, PhD (1) · Christopher Logothetis (1) · Daniel Dumesic, MD (1) · David C. Smith, MD (1) · Eugene Kwon (1) · Joel Picus, MD (1) · Mark D Hurwitz (1) · Mark Hurwitz, MD (1) · Oliver Sartor, MD (1) · Ravi A Madan, M.D. (1) · Ronald D. Ennis, MD (1)
PMID 17194907, PMID 18037582, PMID 18291508, PMID 24950779, PMID 25242417, PMID 31564004, PMID 35780048, PMID 36400597, PMID 37134294
U10CA031946 (2), I01CX002277 (1), P30CA015083 (1), P30CA023074 (1), U10CA032102 (1), U10CA180868 (1)